Posted on

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) announces that further to the Company’s June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.

The Canadian Securities Exchange has published a bulletin confirming that trading will remain halted June 9, 2022, and resume trading on a consolidated basis on Friday, June 10.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences Announces Share Consolidation

Lobe Sciences Announces Share Consolidation

Vancouver, British Columbia–(Newsfile Corp. – June 6, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) announces that its board of directors has authorized the implementation of a consolidation (the “Consolidation”) of the Company’s common shares (the “Shares”) on the basis of one (1) post-Consolidation Share for every six (6) pre-Consolidation Shares, which will become effective on June 9, 2022 (the “Effective Date”). Neither the Company’s name, nor its trading symbols, will change as a result of the Consolidation.

The Company currently has 229,383,983 Shares issued and outstanding. Following the Consolidation, there will be approximately 38,230,000 Shares issued and outstanding. No fractional Shares will be issued, and any fraction of a Share will be rounded up to the nearest whole number of Shares. The Shares will trade on a post-Consolidation basis under the new CUSIP #53946V206 and ISIN #CA53946V2066. The Shares are expected to begin trading on a post-Consolidation basis on the Canadian Securities Exchange when markets open on the Effective Date.

The exercise or conversion price and the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted upon the effectiveness of the Consolidation.

Shareholders of record as of the Effective Date will receive a letter of transmittal providing instructions for the exchange of their Shares as soon as practicable following the Effective Date.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference

Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference

Vancouver, British Columbia–(Newsfile Corp. – March 30, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Company’s webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company’s website or at https://wsw.com/webcast/lytham4/lobef/2174264. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 A.M. – 5:00 P.M. EDT

Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 A.M. – 5:00 P.M. EDT

Vancouver, British Columbia–(Newsfile Corp. – March 23, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company“) announced today that Philip Young, CEO, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT.

Sign up here to access the presentation

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

Click Here to Reserve your seat

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Vancouver, British Columbia–(Newsfile Corp. – March 7, 2022) – Lobe Sciences Ltd. (the “Acquiror“) announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 25, 2022, February 28, 2022, March 2, 2022 and March 3, 2022, it sold at total of 25,254,000 common shares in the capital of Ionic Brands Corp. (the “Issuer” and the common shares of the Issuer referred to as the “Common Shares“), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

As a result of the disposition of Common Shares described herein, the Acquiror owns and has control and direction over 14,360,893 Common Shares, which represents approximately 5% of the Issuer’s issued and outstanding Common Shares on a non-diluted basis.

This press release is issued pursuant to the early warning requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 – Take-Over Bids and Issuer Bids of the Canadian Securities Administrators, which also requires an early warning report to be filed with applicable Canadian securities regulatory authorities containing additional information in respect of the foregoing matters (the “Early Warning Report“). A copy of the Early Warning Report will appear under the Issuer’s profile on the SEDAR website at www.sedar.com. A copy of the Early Warning Report may also be obtained upon request at the contact details below.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115807

Posted on

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Lobe Sciences Ltd. Strengthens Its Balance Sheet

Vancouver, British Columbia–(Newsfile Corp. – February 24, 2022) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (the “Acquiror“) announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 22, 2022 and February 23, 2022, it sold a total of 4,500,000 common shares in the capital of Ionic Brands Corp. (the “Issuer” and the common shares of the Issuer referred to as the “Common Shares“), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets of the Acquiror.

As a result of the disposition of Common Shares described herein, the Acquiror owns and has control and direction over 39,614,893 Common Shares, which represents approximately 15% of the Issuer’s issued and outstanding Common Shares on a non-diluted basis.

This press release is issued pursuant to the early warning requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 – Take-Over Bids and Issuer Bids of the Canadian Securities Administrators, which also requires an early warning report to be filed with applicable Canadian securities regulatory authorities containing additional information in respect of the foregoing matters (the “Early Warning Report“). A copy of the Early Warning Report will appear under the Issuer’s profile on the SEDAR website at www.sedar.com. A copy of the Early Warning Report may also be obtained upon request at the contact details below.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/114713

Posted on

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB® Market in the United States

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB® Market in the United States

Vancouver, British Columbia–(Newsfile Corp. – December 13, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company“) is pleased to announce that it has received approval from OTC Markets Group Inc. (“OTCM”) for its shares to trade on the OTCQB®. Lobe Sciences’ common stock will commence trading on the OTCQB under the symbol “LOBEF” at the opening of the market on December 13, 2021.

Philip Young, CEO & Director, commented, “The admission of our shares on a higher tier of the OTC Marketplace, the OTCQB, is an important step in our development as a publicly traded psychedelic company. The listing is a great achievement for Lobe Sciences as we look to increase investor awareness, broaden our investor base, and continue providing transparency to those seeking investment in our emerging industry.”

Lobe’s listing on the OTCQB provides investors the opportunity to benefit from streamlined market standards which enhance the availability of information to the public, enabling greater transparency. The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial and development stage companies in the United States and abroad. To be listed on OTCQB, companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities and trading.

A comprehensive overview of OTCM’s criteria for qualifying to list on OTCQB can be accessed at the following link: https://www.otcmarkets.com/files/OTCQB_Standards.pdf

The Company has also previously received approval from the Depository Trust Company (“DTC”) to make the Company’s common shares eligible to be electronically cleared and settled through the DTC (DTC Eligible).

This admission of shares to the OTCQB is only applicable to trading in United States and does not represent a material change to the Company or its business activities. Any inquiries regarding this listing may be directed to Lobe’s investor relations department.

About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

The largest and most important Psychedelic Medicine Conference in the Southern Hemisphere

Vancouver, British Columbia–(Newsfile Corp. – November 16, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that it is a Major Supporter of the upcoming International Summit on Psychedelic Therapies for Mental Illness taking place November 17-20, 2021.

Mind Medicine Australia (“MMA”) will hold a two-day online International Summit on Psychedelic Therapies for Mental Illness in November 2021 (the “Summit”), bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, investors, Government, law and policy leaders, business, industry, insurers, consumers, and other interested stakeholders. The Summit will provide the opportunity to learn from the global leaders in the psychedelic renaissance including Dr. Rick Doblin (USA), Professor Roland Griffiths (USA), Professor David Nutt (UK), Dr. Gabor Mate (Canada), Professor Robin Carhart-Harris (UK), Dr Alberto Villoldo (USA) and other thought leaders like Johann Hari.

The event will also feature a two-day pre-Summit Introductory Workshop Program (November 17-18) led by Nigel Denning, Dr. Tra-ill Dowie with world-leading therapist trainer Dr. Bill Richards (USA) from Johns Hopkins University. It is for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.

Philip Young CEO & Director of Lobe Sciences stated, “We are very happy to partner with Mind Medicine Australia by sponsoring this conference and exploring further collaborations as they seek to bring the reality of psychedelic medicine to medical practitioners and their patients in Australia.”

Executive Director of MMA Tania de Jong AM says, “There is a massive renaissance of interest in these medicines, especially now. When we started MMA there was just one commercial start-up globally; now there are new companies launching weekly. With accelerating mental illness across the community due to the Covid-19 crisis we simply do not have the tools to heal the millions who are suffering. These medicines provide potential for healing for those who have tried multiple different treatments, often over decades, without success. We are very excited to hear from the world class leaders at our Global Summit. They will share valuable insights, data and science, and educate practitioners, consumers, insurers, investors, business, industry, government, academics and the broader community about this rapidly emerging field.”

Ilan Hayman, Operations Manager of Mind Medicine Australia and Advisory Board Member of Lobe Sciences said, “Our program features a world class line-up of talks, workshops, hot spots, panel conversations and creative moments. The International Summit on Psychedelic Therapies for Mental Illness is an excellent educational opportunity to gain an in-depth understanding of this long-overdue innovation in mental healthcare. Both MDMA and psilocybin assisted therapies have been shown to be successful in treating depression, social anxiety in autistic adults, post-traumatic stress disorder (PTSD), end-of-life stress and anxiety and addiction. They are now being trialed for anorexia, obsessive-compulsive disorder (OCD), and dementia, among many other conditions. I am very happy that Lobe has partnered with Mind Medicine Australia as we seek to expand the treatment options available to medical practitioners and their patients to treat a range of chronic mental health conditions.”

For information and to register for the International Summit on Psychedelic Therapies for Mental Illness and the Psychedelic Therapist Introductory Workshop, please visit: https://summit.mindmedicineaustralia.org/.

About Mind Medicine Australia

Mind Medicine Australia was founded by social entrepreneurs Peter Hunt AM and Tania de Jong AM following their successful experience setting up other charities and working with people diagnosed with a mental illness. It is an Australian registered charity (with DGR 1 status) seeking to broaden the treatment paradigm available to medical practitioners and their patients and improve treatment effectiveness by establishing, safe, accessible and effective Psychedelic-Assisted Psychotherapy in Australia to help prevent further suffering and suicides caused by mental illness. MMA’s focus in wholly clinical.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.

Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103631

Posted on

Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets

Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets

Vancouver, British Columbia–(Newsfile Corp. – November 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that its common stock ticker will change from “GTSIF” to “LOBEF” and will commence trading under the symbol “LOBEF” in US markets at the opening of the market on November 15, 2021 and will continue to trade under the ticker symbol “LOBE” on the CSE.

Philip Young, CEO, commented, “The ticker change now reflects the name of the company along with our commitment to investigating and developing treatments using alternative and nontraditional medicines to better brain health.”

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103486

Posted on

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience

Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Krysalis VX Innovations Inc. (“Krysalis”), the Virtual experience (“VX”)-focused company designing the delivery of immersive, headset-free experiences through the KrysalisTM Pod system that will offer treatment options for cognitive, psychological, motor and functional impairments across various clinical health conditions, has appointed a distinguished and future-facing advisory team composed of Alex McDowell, Jon 9, Austin Blaisdell, and the three minds behind sonic engineering company, Resonant Devices, Kent Noonan, Erik Larson and Casey Atteberry.

Krysalis was formed pursuant to a joint venture agreement between Lobe and Virtual Psychedelics Incorporated (“VPI”) announced on April 27, 2021, where Krysalis is owned 50% by Lobe and 50% by VPI.

This advisory group will assist Krysalis through its first iteration of the KrysalisTM Pod. The current leadership team of Krysalis, CEO and social network-transmedia pioneer, Josh Shore; Hollywood director, futurist, and KrysalisTM Pod project lead, Brett Leonard; Professor and Director of Medical Virtual Reality at USC’s Institute for Creative Technologies, Dr. Albert (Skip) Rizzo; and VIP Event Producer, William (Billy) Alfonso (Formula-1, Cirque du Soleil) – are thrilled that the KrysalisTM Pod development will now benefit from representation and expertise of the advisory team that spans across arts, technology, design, academic and industry sectors.

“As a cinematic storyteller, having told cautionary tales of the transformative power of Virtual Reality in my movies, to now be involved in the actual reality of using this technology thanks to our groundbreaking partnership with Lobe Sciences and the incredible advisory group being announced here, is the realization of my greatest hopes for Virtual eXperience (VX) to be a positive force for healing the human spirit,” said Brett Leonard. “The best part is, with the development of the KrysalisTM Pod, no one in these therapeutic environments will have to strap an uncomfortable device on their head.”

Krysalis is committed to further developing systems that deliver virtual experience in tandem with psychedelics for research and clinical therapy, developing VR systems without psychedelics for recreational purposes such as gaming, and is focused on the development of the KrysalisTM Pod. The KrysalisTM Pod is new technology that will harness biometric feedback to make visible the tangible combined effects of virtual reality (“VR”) and psychedelics on biometric activity in real time. With this ability, the implementer (researcher or clinician) will be able to monitor both the psychedelic and the immersive experience such that it will be uniquely tailored to individual responses, and thus moderated to maximize the desired effect and therapeutic outcomes.

“I am impressed with the depth and capabilities of the Advisory team assembled by Krysalis management,” said Philip Young, CEO Lobe Sciences Ltd. “We have confidence that working together they will be able to create an industry leading VX experience that may aid those suffering from depression, PTSD and other mental health issues.”

This advisory team will be pivotal in defining aesthetic and pragmatic attributes of Krysalis VX’s treatment-oriented technology. The advisory team consists of:

Alex McDowell Award-winning designer, storyteller, and founder and creative director of Experimental Design where McDowell and his team design immersive story worlds for industries and institutions. He is simultaneously a professor of practice at USC School of Cinema, where he directs the World Building Media Lab and World Building Institute and teaches world building as a media and platform-agnostic narrative design practice. Alex is also known as one of the top Hollywood production designers, having worked on some of the biggest visionary Hollywood blockbusters such as Steven Spielberg’s “Minority Report”.

Jon 9 is a Creative Technologist who handles large-scale digital display projects, streaming immersive spaces, content creation and post-production management for complex systems. He’s realized massive projects including Cirque du Soleil: Beatles LOVE at The Mirage Las Vegas, installations with Disney, and many others with icons and mega-brands from Michael Jackson and Aretha Franklin to Audi and The Emmy Awards. His expertise is rooted in developing experiential media spaces that require new techniques and technologies.

Austin Blaisdellis a design strategist and art director who uses 3D printing, Virtual Reality, and the entire digital universe to project visions spanning all arts-related genres. His spatial design, visual direction, and design solutions may be experienced internationally, at exhibitions from Los Angeles to New York to Paris.

Kent Noonan is an Electronic Engineer whose expertise spans all areas of design and manufacturing, lasers and optics, high performance electronics and tough industrial devices, alternative healing with light and electromagnetic frequencies, free energy devices and alternate fuels, plasma, cymatics, and structured water research.

Erik Larsonis an inventor, design engineer, musician, instrument builder, and entrepreneur. His professional specialties include business development, business management, patent and IP development, product development, technology integration, systems design, and team building.

Casey Atteberry is a mathematician striving to translate material in an approachable way to people of all ages and levels of interest. He has been an independent math and acoustical physics research scientist for nearly two decades, studying concepts from quantum computation to cymatics and fluid dynamics.

* * *

About Krysalis VX Innovations Inc.

Krysalis VX Innovations Inc. exists to design sophisticated, immersive treatments for psychological, cognitive and physical challenges. The KrysalisTM Pod will be designed to be powered by a custom tech stack incorporating advanced display technology and state-of-the-art bio-monitoring with the goal of improving psychedelic therapy by optimizing set, setting and the overall experience for clinical and other uses. The KrysalisTM Pod will deliver headset-free, virtual experiences that integrate multi-sensory stimulation to create an application that can offer treatment options for cognitive, psychological, motor and functional impairments across a wide range of clinical health conditions.

About Virtual Psychedelics Incorporated (“VPI”)

VPI was formed to pioneer the integration of Psychedelic Therapies with Virtual Experience known as “VX” (Virtual Reality, Augmented Reality & Mixed Reality). Founded by the leading minds in both clinical and entertainment-based Virtual Reality, VPI is dedicated to developing new approaches for the treatment of neurological and psychiatric conditions, and for promoting wellness, alongside the technologies and processes to make them scalable. In addition to medicinal applications, this marriage of ancient and modern technologies has enormous potential for promoting self-understanding and social transformation.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

For press inquiries on Krysalis, please contact Jessie Cohen PR & Consulting:
Jessie Cohen
jessie@jessieiscohen.com
+1 415 623 0150

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, statements related to the development and commercialization of the KrysalisTMPod, including systems, treatments and benefits thereof, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices, including the KrysalisTMPod, produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; Krysalis may be unsuccessful in designing and commercializing the KrysalisTM Pod and/or the risk that the Company may not realize a return on its investment in Krysalis; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.